Terms: = Ovarian cancer AND NCOR2, SMRTE-tau, 9612, ENSG00000196498, SMRTE, TNRC14, TRAC-1, SMRT, CTG26, TRAC1 AND Treatment
5 results:
1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
2. A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in ovarian cancer.
Pi Y; Sun F; Zhang Z; Liu X; Lou G
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512088
[No Abstract] [Full Text] [Related]
3. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
[TBL] [Abstract] [Full Text] [Related]
4. Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer.
Langer W; Sohler F; Leder G; Beckmann G; Seidel H; Gröne J; Hummel M; Sommer A
BMC Genomics; 2010 Nov; 11():676. PubMed ID: 21118496
[TBL] [Abstract] [Full Text] [Related]
5. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting.
Kelley KM; Rowan BG; Ratnam M
Cancer Res; 2003 Jun; 63(11):2820-8. PubMed ID: 12782587
[TBL] [Abstract] [Full Text] [Related]
